Cachexia - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 42
Inquire Before Buying

Cachexia - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cachexia - Pipeline Review, H2 2017, provides an overview of the Cachexia (Musculoskeletal Disorders) pipeline landscape.

Cachexia is the dramatic weight loss and muscle atrophy seen in patients with chronic illness including type I diabetes, multiple sclerosis, HIV, cancer, and in individuals with age-associated „failure to thrive? syndrome. Symptoms include involuntary (unintentional) weight loss, skeletal muscle wasting, anorexia/loss of appetite, lowered quality of life. Treatment includes diet, nutritional supplements, exercise and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cachexia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cachexia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cachexia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Cachexia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 5, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Cachexia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cachexia (Musculoskeletal Disorders).

- The pipeline guide reviews pipeline therapeutics for Cachexia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cachexia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cachexia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cachexia (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cachexia (Musculoskeletal Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cachexia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Cachexia - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cachexia - Overview
Cachexia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cachexia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cachexia - Companies Involved in Therapeutics Development
Aphios Corp
Connexios Life Sciences Pvt Ltd
GlaxoSmithKline Plc
India Globalization Capital, Inc.
MYOS RENS Technology Inc
Teijin Pharma Ltd
Vascular BioSciences
Cachexia - Drug Profiles
ARM-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-1889 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAR Peptide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNX-013B2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2881078 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IGC-504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target Melanocortin-4 Receptor for Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEISARM-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cachexia - Dormant Projects
Cachexia - Discontinued Products
Cachexia - Product Development Milestones
Featured News & Press Releases
Jun 04, 2002: Aphios Receives National Cancer Institute Grant For Developing Natural Cannabinoid Products for Medical Use
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Cachexia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Cachexia - Pipeline by Aphios Corp, H2 2017
Cachexia - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017
Cachexia - Pipeline by GlaxoSmithKline Plc, H2 2017
Cachexia - Pipeline by India Globalization Capital, Inc., H2 2017
Cachexia - Pipeline by MYOS RENS Technology Inc, H2 2017
Cachexia - Pipeline by Teijin Pharma Ltd, H2 2017
Cachexia - Pipeline by Vascular BioSciences, H2 2017
Cachexia - Dormant Projects, H2 2017
Cachexia - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Cachexia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Global Circulating Tumor Cells Market Research Report 2017
    Published: 10-Nov-2017        Price: US 2900 Onwards        Pages: 115
    In this report, the global Circulating Tumor Cells market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Circulating Tumor Cells in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Ch......
  • Biliary Tumor - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Biliary Tumor - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Biliary Tumor. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Biliary Tumor which can turn out to b......
  • Chemotherapy Induced Anemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Chemotherapy Induced Anemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Chemotherapy Induced Anemia. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Chemother......
  • Larynx Cancer -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Larynx Cancer - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Larynx Cancer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Larynx Cancer prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Larynx ......
  • Hodgkin's lymphoma (HL) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Hodgkin's lymphoma (HL) - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Hodgkin's lymphoma (HL) - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagno......
  • Lip and Oral Cavity Cancer -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Lip and Oral Cavity Cancer - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Lip and Oral Cavity Cancer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Lip and Oral Cavity Cancer prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet m......
  • Liver cancer -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Liver cancer - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Liver cancer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Liver cancer prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Liver cancer.......
  • Small Cell Lung Cancer - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Small Cell Lung Cancer - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Small Cell Lung Cancer for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Small Cell Lung Cancer . It enables unde......
  • Epithelial Ovarian Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Epithelial Ovarian Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Epithelial Ovarian Cancer. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Epithelial Ov......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs